rc28-e
mAbexperimentalMulti-specific
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Oct 9, 2018 (NCT03777254)
Timeline
Indications
Mechanism of action
- Basic fibroblast growth factorINHIBITOR
FGF2 inhibitor
- Vascular endothelial growth factor AINHIBITOR
VEGFA inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05885503 | Phase 3 | Jun 8, 2023 | Chinese Academy of Medical Sciences, RemeGen |
| NCT05727397 | Phase 3 | Mar 14, 2023 | RemeGen |
| NCT04782128 | Phase 2 | May 25, 2021 | RemeGen |
| NCT04782115 | Phase 2 | Mar 17, 2021 | RemeGen |
| NCT04270669 | Phase 1/Phase 2 (Phase 2) | Feb 29, 2020 | RemeGen |
| NCT03777254 | Phase 1 | Oct 9, 2018 | Capital Medical University, RemeGen |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| RemeGen | For profit | 6 | 6 | 3 | 2018 |
| Capital Medical University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1